Vanguard Group Inc Atreca, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.13 - $0.38 $54,550 - $159,456	-419,623 Reduced 31.58%	909,300 $118,000
Q4 2022 Feb 10, 2023	BUY	$0.78 - $1.68 $490 - $1,056	629 Added 0.05%	1,328,923 $1.06 Million
Q3 2022 Nov 14, 2022	BUY	$1.59 - $2.74 $69,180 - $119,217	43,510 Added 3.39%	1,328,294 $2.09 Million
Q2 2022 Aug 12, 2022	BUY	$1.56 - $3.25 $91,731 - $191,106	58,802 Added 4.8%	1,284,784 $2.3 Million
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $176,538 - $570,185	-109,651 Reduced 8.21%	1,225,982 $3.89 Million

Q4 2021 Feb 14, 2022	SELL	$2.87 - $6.29 $81,390 - $178,378	-28,359 Reduced 2.08%	1,335,633 $4.05 Million
Q3 2021 Nov 12, 2021	BUY	$4.91 - $9.07 $58,350 - $107,787	11,884 Added 0.88%	1,363,992 $8.5 Million
Q2 2021 Aug 13, 2021	BUY	$7.82 - $13.8 $10.6 Million - $18.7 Million	1,352,108 New	1,352,108 $11.5 Million

1.04M

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Market Cap $2.87M
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.